Tandem Diabetes Care (TNDM) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.31
- EPS estimate
- −$0.32
- EPS surprise
- +4.37%
- Revenue surprise
- −0.17%
- Revenue
- $254.6M
- Revenue estimate
- $255.0M
- Reported
- Aug 6, 2026
Tandem Diabetes Care reported Q2 2026 results on August 6, 2026. The company posted a loss of $0.31 per share, slightly narrower than the $0.32 loss expected, a 4.37% beat. Revenue was $254.6 million, just under the $255.0 million consensus. Compared with Q2 2025, the loss narrowed from $0.48 per share and revenue rose about 6% from $240.7 million.
Tandem lost money in 17 of the last 20 quarters; the profitable ones were Q3 2021, Q4 2021 and Q4 2024. Annual losses were $1.48 per share in 2022, $3.44 in 2023, $1.46 in 2024 and $1.47 in 2025. Revenue has grown, from $762.3 million in 2023 to $1.01 billion in 2025, and the fourth quarter has been the strongest of each recent year, with Q4 2025 setting the high here at $290.4 million. The first-half 2026 loss of $0.61 per share compares with $1.15 a year earlier. Tandem beat the EPS estimate in 9 of the last 20 quarters, including 6 of the last eight.
Third-quarter results have come out between November 1 and November 6 in each of the past five years. That points to early November 2026 for the Q3 2026 report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.32 | −$0.31 | +4.37% | $254.6M | SEC |
| Q1 2026 | May 7, 2026 | −$0.44 | −$0.30 | +32.79% | $247.2M | SEC |
| Q4 2025 | Feb 19, 2026 | −$0.09 | −$0.01 | +90.42% | $290.4M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.33 | −$0.31 | +4.98% | $249.3M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.40 | −$0.48 | −20.93% | $240.7M | SEC |
| Q1 2025 | Apr 30, 2025 | −$0.60 | −$0.67 | −10.61% | $234.4M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.20 | $0.01 | +104.90% | $252.4M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.40 | −$0.35 | +13.17% | $242.9M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.54 | −$0.47 | +12.18% | $221.8M | SEC |
| Q1 2024 | May 2, 2024 | −$0.76 | −$0.65 | +14.19% | $192.8M | SEC |
| Q4 2023 | Feb 21, 2024 | −$0.26 | −$0.46 | −74.31% | $209.4M | SEC |
| Q3 2023 | Nov 1, 2023 | −$0.48 | −$0.51 | −6.10% | $185.6M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.50 | −$0.55 | −9.17% | $195.9M | SEC |
| Q1 2023 | May 3, 2023 | −$0.54 | −$1.92 | −256.55% | $171.4M | SEC |
| Q4 2022 | Feb 22, 2023 | −$0.08 | −$0.25 | −207.88% | $220.5M | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.07 | −$0.76 | −1053.26% | $205.1M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.02 | −$0.24 | −1463.64% | $200.3M | SEC |
| Q1 2022 | May 4, 2022 | −$0.07 | −$0.23 | −226.70% | $175.9M | SEC |
| Q4 2021 | Feb 22, 2022 | $0.21 | $0.16 | −23.66% | $210.0M | SEC |
| Q3 2021 | Nov 3, 2021 | $0.06 | $0.09 | +57.62% | $179.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Tandem Diabetes Care (TNDM) last report earnings?
Tandem Diabetes Care last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did TNDM beat earnings estimates?
Yes. Tandem Diabetes Care reported EPS of −$0.31 for Q2 2026 against a −$0.32 estimate — a 4.37% beat.
How much revenue did TNDM report last quarter?
Tandem Diabetes Care reported $254.6M in revenue for Q2 2026, against a consensus estimate of $255.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.